13F Holdings
中文EN

INKT MiNK Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1840229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY10.8%
TTM EPS YoY25.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-95.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets297.2%
Debt / equity—
Current ratio0.97x
Interest coverage317.82x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-33.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$5.76M$6.34M$15.49M$23.12M$13.97M
SG&A expense$6.73M$4.31M$7.43M$7.83M$4.64M
Operating income-$12.64M-$11.29M-$22.92M-$30.95M-$28.36M
Interest expense-$110,000-$93,000-$28,000—$2.43M
Net income-$12.49M-$10.78M-$22.46M-$27.99M-$30.21M
EBITDA-$12.46M-$11.07M-$22.72M-$30.83M-$28.28M
EPS (basic)-2.93-2.86-6.54-0.83-1.16
EPS (diluted)-2.93-2.86-6.54-0.83-1.16
Weighted avg. shares (diluted)4.27M3.77M3.44M33.67M26.03M
Banking
Net interest income$180,246$172,568$463,256$253,323-$2.43M
Balance sheet
Cash & equivalents$13.36M$4.58M$3.37M$19.64M$38.89M
Current assets$13.85M$4.99M$3.60M$20.40M$39.63M
PP&E, net$390,869$732,929$953,977$1.07M$606,595
Total assets$14.24M$5.72M$4.55M$21.47M$40.24M
Current liabilities$13.03M$6.96M$11.40M$12.68M$16.47M
Total liabilities$28.47M$25.31M$22.61M$21.87M$16.47M
Shareholders' equity-$14.23M-$19.59M-$18.06M-$401,303$23.78M
Shares outstanding4.71M3.96M3.46M33.86M33.48M
Cash flow statement
Operating cash flow-$5.93M-$9.56M-$15.76M-$18.87M-$12.83M
Capital expenditure——$73,561$250,046$248,983
Free cash flow——-$15.84M-$19.12M-$13.08M
Investing cash flow——-$73,561-$250,046-$248,983
Financing cash flow$14.72M$10.82M-$407,173-$155,599$49.26M
Depreciation & amortization$181,745$215,437$204,617$121,749$77,960
Stock-based compensation$2.67M$1.81M$3.86M$3.03M$1.74M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.